<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03810690</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-3704-P101</org_study_id>
    <nct_id>NCT03810690</nct_id>
  </id_info>
  <brief_title>Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia</brief_title>
  <official_title>A Global, Phase 1/2, Open Label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This First-in-Human (FIH) Phase 1/2 study will evaluate mRNA-3704 in patients with
      methylmalonic acidemia/aciduria (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency
      between 1 to 18 years of age with elevated plasma methylmalonic acid. The study is designed
      to characterize baseline biomarker levels followed by assessment of safety, pharmacokinetics,
      and pharmacodynamics of different doses of mRNA-3704 in patients affected by MMA as part of
      the Dose Escalation phase.

      During the Dose Escalation phase, three dose levels of mRNA-3704 are planned to be
      investigated in this study among patients with MMA due to MUT deficiency: low dose, mid dose,
      and high dose. An additional cohort to evaluate a fourth dose level may be considered jointly
      by the independent SMC and the Sponsor.

      Upon establishment of a dose with acceptable safety and pharmacodynamic activity, additional
      patients will be enrolled in a Dose Expansion phase to allow for further characterization of
      the safety and pharmacodynamics of mRNA-3704.

      Patients in both phases of study will participate in a pre-dosing observational period,
      followed by a treatment period, and then a follow-up period after withdrawal of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Day 1 (initial mRNA-3704 dose) through 52 weeks after final mRNA-3704 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma methylmalonic acid levels</measure>
    <time_frame>Week -4 through 36 weeks after initial mRNA-3704 dose</time_frame>
    <description>Baseline (pre-dose levels) to post-dose levels measured after single and after repeated administrations of mRNA-3704</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) after administration of mRNA-3704</measure>
    <time_frame>Baseline through 36 weeks after initial mRNA-3704 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax)</measure>
    <time_frame>Baseline through 36 weeks after initial mRNA-3704 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Baseline through 36 weeks after initial mRNA-3704 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma 2-methylcitrate levels</measure>
    <time_frame>Week -4 through 36 weeks after initial mRNA-3704 dose</time_frame>
    <description>Baseline (pre-dose levels) to levels measured after single and after repeated administrations of mRNA-3704</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of anti-PEG antibodies</measure>
    <time_frame>Pre-dose through up to 52 weeks after final mRNA-3704 dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Methylmalonic Acidemia (MMA)</condition>
  <condition>Metabolism, Inborn Errors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-3704</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Phase: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-3704</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Phase: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-3704</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Phase: Dose Level 4 (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-3704</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase: mRNA-3704</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-3704</intervention_name>
    <description>mRNA-3704 dispersion for intravenous (IV) infusion</description>
    <arm_group_label>Dose Escalation Phase: Dose Level 1</arm_group_label>
    <arm_group_label>Dose Escalation Phase: Dose Level 2</arm_group_label>
    <arm_group_label>Dose Escalation Phase: Dose Level 3</arm_group_label>
    <arm_group_label>Dose Escalation Phase: Dose Level 4 (optional)</arm_group_label>
    <arm_group_label>Dose Expansion Phase: mRNA-3704</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are eligible to be included in the study only if all of the following criteria
        apply:

          -  Confirmed diagnosis of isolated MMA due to MUT deficiency based on the following
             criteria:

               -  Elevated plasma methylmalonic acid concentrations (≥ 100 µmol/L)

               -  Presence of normal serum/plasma Vitamin B12 and plasma homocysteine levels

               -  Confirmed diagnosis by molecular genetic testing

          -  Patient must be ≥ 1 year of age at the time of consent/assent (Inclusion of the first
             three patients will be restricted to individuals age ≥ 8 years)

        Exclusion Criteria:

        Patients are excluded from the study if any of the following criteria apply:

          -  Diagnosis of isolated MMA cblA, cblB, or cblD enzymatic subtypes or methylmalonyl-CoA
             epimerase deficiency or combined MMA with homocystinuria

          -  History of organ transplantation

          -  Previously received gene therapy for the treatment of MMA.

          -  Estimated glomerular filtration rate (GFR) &lt; 30 mL/min/1.73 m2; or patients who
             receive chronic dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Children's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospitals &amp; Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

